What is Acacia Pharma Group?
Acacia Pharma Group plc is a pharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products designed for patients undergoing surgery, invasive procedures, or chemotherapy. The company's pipeline includes key products such as BARHEMSYS, an intravenous amisulpride for post-operative nausea and vomiting, and BYFAVO, a reversible IV sedative for invasive medical procedures. Additionally, APD403, a selective dopamine antagonist amisulpride, is in late-stage clinical trials for chemotherapy-induced nausea and vomiting. Founded in 2007 and based in Cambridge, UK, Acacia Pharma Group operates within the critical care and oncology therapeutic areas, aiming to address unmet patient needs.
How much funding has Acacia Pharma Group raised?
Acacia Pharma Group has raised a total of $33.5M across 2 funding rounds:
Series A
$10M
Series B
$23.5M
Series A (2011): $10M with participation from Gilde Healthcare and Lundbeckfond Ventures
Series B (2013): $23.5M led by Lundbeckfond Ventures, Novo A/S, and Gilde Healthcare
Key Investors in Acacia Pharma Group
Lundbeckfond Ventures
Lundbeckfond Ventures is a venture capital arm of the Lundbeck Foundation, focusing on biomedical research and companies within the life sciences sector. Their investment in Acacia Pharma Group suggests a strategic interest in pharmaceutical innovation and therapeutic development.
Novo A/S
Novo A/S, part of Novo Holdings, is a Danish investment company with a strong presence in the life sciences and healthcare industries. Their participation in Acacia Pharma Group's funding round highlights their commitment to advancing pharmaceutical companies with promising drug candidates.
Gilde Healthcare
Gilde Healthcare is a specialized investment firm with a focus on the healthcare sector, managing venture and growth capital. Their involvement indicates a belief in Acacia Pharma Group's business model and its potential for significant returns within the pharmaceutical market.
What's next for Acacia Pharma Group?
With the recent strategic investment and a history of substantial backing, Acacia Pharma Group is well-positioned for its next phase of growth. The company's focus on developing novel treatments for significant medical challenges suggests a trajectory towards scaling its operations and expanding market reach. Future endeavors will likely involve advancing its product pipeline through further clinical trials, securing regulatory approvals, and establishing robust commercialization strategies. The enterprise-level funding indicates confidence from investors in Acacia Pharma's potential to deliver impactful pharmaceutical solutions.
See full Acacia Pharma Group company page
